View on Pubmed.gov 28259657 | View on doi.org 10.1016/j.neule...
Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma.
- Institute of Pharmacology, Catholic University Medical School, L.go F. Vito 1, Rome, 00168, Italy. Electronic address: lucia.lisi@unicatt.it.
- Institute of Pharmacology, Catholic University Medical School, L.go F. Vito 1, Rome, 00168, Italy. Electronic address: gabriella.ciotti@hotmail.it.
- Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: brauny@gmail.com.
- Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: sergey@uic.edu.
- Institute of Pharmacology, Catholic University Medical School, L.go F. Vito 1, Rome, 00168, Italy. Electronic address: diego.curro@unicatt.it.
- Institute of Pharmacology, Catholic University Medical School, L.go F. Vito 1, Rome, 00168, Italy. Electronic address: cinzia.dellorusso@unicatt.it.
- Institute of Pathology, Catholic University Medical School, Rome, Italy. Electronic address: antonella.coli@rm.unicatt.it.
- Institute of Neurosurgery, Catholic University Medical School, Rome, Italy. Electronic address: amangiola@rm.unicatt.it.
- Institute of Neurosurgery, Catholic University Medical School, Rome, Italy. Electronic address: anilec@rm.unicatt.it.
- Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL, USA; Department of Veterans Affairs, Jesse Brown VA Medical Center, Chicago, IL, USA. Electronic address: dlfeins@uic.edu.
- Institute of Pharmacology, Catholic University Medical School, L.go F. Vito 1, Rome, 00168, Italy. Electronic address: pierluigi.navarra@unicatt.it.
Abstract
Microglia and macrophages appear to be the most common cells in the GBM microenvironment. In the present study we investigated the status of macrophages/microglia activation in surgical specimens from 41 patients diagnosed with grade IV GBM. For each patient we analyzed both the center of tumor and the parenchyma surrounding the tumor. The specimens were stained for: i) IBA1, a 17-kDa EF hand protein specifically expressed in microglia/macrophages ii) CD163, a cell surface antigen associated with M2 phenotype; iii) iNOS, taken as a functional marker of M1 phenotype, and iv) ARG-I, taken as a functional marker of M2 phenotype. Staining was scored in a double-blinded score on a scale from 0 to 5. Our results suggest that CD163 expression is higher within the tumor than in surrounding periphery in both male and female patients; while iNOS is higher within the tumor in males, no significant difference was found for ARG-1. In addition, analyzing the data in TGCA database, we found that CD163 expression was significantly and inversely correlated with mean survival times, with average survival times ranging from 448days in patients having low expression, to 319 in mid, and 353 in patients with high CD163 expressing tumors. In contrast, no significant association was found between survival time and ARG-1 or iNOS expression.
References
Cited by 232 citations (total)
Journal Article Review
Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.
Electronic publication date June 22, 2021
Jun Ma [...] Ming Li et al.
The complex interaction between glioblastoma and its microenvironment has been recognized for decades. Among various immune profiles, the major population...
Journal Article Research Support, Non-U.S. Gov't
Sphingomyelin Synthase 2 Inhibition Ameliorates Cerebral Ischemic Reperfusion Injury Through Reducing the Recruitment of Toll-Like Receptor 4 to Lipid Rafts.
Electronic publication date December 15, 2020
Jing Xue [...] Shucun Qin et al.
Background Inflammation is recognized as an important contributor of ischemia/reperfusion (I/R) damage after ischemic stroke. Sphingomyelin synthase 2 (SMS2), the...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
Copyright
Copyright © 2017 Elsevier B.V. All rights reserved.